Where can I buy Sotorasib in Hong Kong?

Sotorasib (Sotorasib) is an innovative anti-cancer drug that belongs to KRAS G12C inhibitors are used to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS geneG12C mutations. KRASgene mutations are quite common in cancer, especially in NSCLC, so the development of sotorasiib fills the long-standing gap in the treatment of this gene mutation.

The original drug of sotorasibu has not yet been launched in China, so patients cannot purchase it domestically and need to purchase sotorasibu through overseas channels. The price of the original version of sotorasibu in Hong Kong, China, with the specifications of 120mg*240 tablets, is around 8 million, and the price of the European version of the original drug with the same specifications is around 4 million, which is relatively expensive. The cheaper ones are the generic drugs marketed abroad. For example, the price of generic drugs in Laos and Bangladesh is around two to three thousand yuan. The price is relatively cheap, and the ingredients of foreign generic drugs are basically the same as the original drugs.

This drug is unique in that it is the first treatment to directly interfere with the KRAS G12C mutation. KRASThe gene plays a key role in regulating cell growth and differentiation. When its G12C site is mutated, it will cause cells to lose normal growth control, thus promoting the occurrence of cancer. Sotoracib blocks the growth signaling of cancer cells by specifically inhibiting the KRAS G12C mutation, thereby potentially inhibiting tumor development.

Clinical trial results show that sotoraxib has significant efficacy in some KRAS G12CmutatedNSCLC patients, bringing new hope to this patient group. This marks an important breakthrough in scientists' long-standing efforts to treat KRAS genes, as directly interfering with KRAS genes has been considered an extremely challenging task in the past.